Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1997 1
2008 1
2009 1
2012 4
2013 5
2014 3
2015 2
2016 2
2017 1
2018 1
2019 2
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

24 results
Results by year
Filters applied: . Clear all
Page 1
Quantifying Intranasally Administered Deferoxamine in Rat Brain Tissue with Mass Spectrometry.
Kosyakovsky J, Witthuhn BA, Svitak AL, Frey WH 2nd, Hanson LR, Fine JM. Kosyakovsky J, et al. ACS Chem Neurosci. 2019 Nov 20;10(11):4571-4578. doi: 10.1021/acschemneuro.9b00436. Epub 2019 Oct 15. ACS Chem Neurosci. 2019. PMID: 31573798
Deferoxamine, a metal chelator, has been shown to be neuroprotective in animal models of ischemic stroke, traumatic brain injury and both subarachnoid and intracerebral hemorrhage. Intranasal deferoxamine (IN DFO) has also shown promise as a potential treatme …
Deferoxamine, a metal chelator, has been shown to be neuroprotective in animal models of ischemic stroke, traumatic brain injury and …
Intranasal administration of CNS therapeutics to awake mice.
Hanson LR, Fine JM, Svitak AL, Faltesek KA. Hanson LR, et al. J Vis Exp. 2013 Apr 8;(74):4440. doi: 10.3791/4440. J Vis Exp. 2013. PMID: 23608783 Free PMC article.
Efficacy of therapeutics administered intranasally in this way to mice has been demonstrated in a number of studies including insulin in diabetic mouse models and deferoxamine in Alzheimer's mouse models. ...We have prepared this JoVE video to make this intranasa …
Efficacy of therapeutics administered intranasally in this way to mice has been demonstrated in a number of studies including insulin …
Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.
Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule MB, Shoyele SA, Alexander A. Agrawal M, et al. J Control Release. 2018 Jul 10;281:139-177. doi: 10.1016/j.jconrel.2018.05.011. Epub 2018 May 24. J Control Release. 2018. PMID: 29772289 Review.
In this context, the intranasal (IN) route of drug administration has emerged as an alternative route over the systemic (oral and parenteral) drug delivery to the brain. ...These agents include galantamine, deferoxamine, tacrine, tarenflurbil, rivastigmine, risperid …
In this context, the intranasal (IN) route of drug administration has emerged as an alternative route over the systemic (oral and par …
Intranasal deferoxamine affects memory loss, oxidation, and the insulin pathway in the streptozotocin rat model of Alzheimer's disease.
Fine JM, Forsberg AC, Stroebel BM, Faltesek KA, Verden DR, Hamel KA, Raney EB, Crow JM, Haase LR, Knutzen KE, Kaczmarczek KD, Frey WH, Hanson LR. Fine JM, et al. J Neurol Sci. 2017 Sep 15;380:164-171. doi: 10.1016/j.jns.2017.07.028. Epub 2017 Jul 21. J Neurol Sci. 2017. PMID: 28870559
Deferoxamine (DFO) is a metal chelator found to be beneficial in several animal models of neurodegenerative disease and insult including Alzheimer's disease, Parkinson's disease, stroke, and subarachnoid hemorrhage. In this study, we determine whether intranasally ( …
Deferoxamine (DFO) is a metal chelator found to be beneficial in several animal models of neurodegenerative disease and insult includ …
Comparison of the effects of nimodipine and deferoxamine on brain injury in rat with subarachnoid hemorrhage.
Qin Y, Li G, Sun Z, Xu X, Gu J, Gao F. Qin Y, et al. Behav Brain Res. 2019 Jul 23;367:194-200. doi: 10.1016/j.bbr.2019.04.004. Epub 2019 Apr 3. Behav Brain Res. 2019. PMID: 30953658
These rats were injected with saline (intraperitoneal, IP), nimodipine (IP), or deferoxamine (IP and intranasal) every 12 h for 5 days after SAH. ...Deferoxamine effectively reduced neuronal cell death and ameliorated cognitive function after SAH....
These rats were injected with saline (intraperitoneal, IP), nimodipine (IP), or deferoxamine (IP and intranasal) every 12 h fo …
Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice.
Hanson LR, Fine JM, Renner DB, Svitak AL, Burns RB, Nguyen TM, Tuttle NJ, Marti DL, Panter SS, Frey WH 2nd. Hanson LR, et al. Drug Deliv Transl Res. 2012 Jun;2(3):160-8. doi: 10.1007/s13346-011-0050-2. Drug Deliv Transl Res. 2012. PMID: 25786865
The purpose of this study was to both determine concentrations of deferoxamine (DFO), a high-affinity iron chelator, reaching the brains of mice after intranasal administration and to determine its efficacy in a mouse model of spatial memory loss. ...This is the fir …
The purpose of this study was to both determine concentrations of deferoxamine (DFO), a high-affinity iron chelator, reaching the bra …
Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F, Andersen KJ, Sanchez-Guajardo V, Tentillier N, Romero-Ramos M. Febbraro F, et al. Exp Neurol. 2013 Sep;247:45-58. doi: 10.1016/j.expneurol.2013.03.017. Epub 2013 Mar 24. Exp Neurol. 2013. PMID: 23531432
Rats were treated with a novel deferoxamine delivery approach: 6 mg of the compound was administered intranasally three times a week for 3 or 7 weeks. ...Our data show that although intranasal administration of deferoxamine in rats did not protect them …
Rats were treated with a novel deferoxamine delivery approach: 6 mg of the compound was administered intranasally three times …
Intranasal deferoxamine attenuates synapse loss via up-regulating the P38/HIF-1α pathway on the brain of APP/PS1 transgenic mice.
Guo C, Zhang YX, Wang T, Zhong ML, Yang ZH, Hao LJ, Chai R, Zhang S. Guo C, et al. Front Aging Neurosci. 2015 Jun 2;7:104. doi: 10.3389/fnagi.2015.00104. eCollection 2015. Front Aging Neurosci. 2015. PMID: 26082716 Free PMC article.
In the present study, we observed that intranasal administration of deferoxamine decreased beta-amyloid (Aβ) deposition and rescued synapse loss in the brain of Aβ precursor protein and presenilin-1 (APP/PS1) double transgenic mice. We found that deferoxamine …
In the present study, we observed that intranasal administration of deferoxamine decreased beta-amyloid (Aβ) deposition and re …
Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation.
Fine JM, Renner DB, Forsberg AC, Cameron RA, Galick BT, Le C, Conway PM, Stroebel BM, Frey WH 2nd, Hanson LR. Fine JM, et al. Neurosci Lett. 2015 Jan 1;584:362-7. doi: 10.1016/j.neulet.2014.11.013. Epub 2014 Nov 13. Neurosci Lett. 2015. PMID: 25445365
One chelator currently being developed is deferoxamine (DFO), administered via the intranasal (IN) route. In the current study, APP/PS1 amyloid mice were treated with a chronic, low dose of IN DFO, subjected to a rigorous battery of behavior tests, and the mechanism …
One chelator currently being developed is deferoxamine (DFO), administered via the intranasal (IN) route. In the current study …
Intranasal administration of deferoxamine to iron overloaded patients.
Gordon GS, Ambruso DR, Robinson WA, Githens JH. Gordon GS, et al. Am J Med Sci. 1989 May;297(5):280-4. doi: 10.1097/00000441-198905000-00002. Am J Med Sci. 1989. PMID: 2640419
We examined the effect of intranasal administration of deferoxamine on iron excretion in seven patients with iron overload secondary to chronic transfusion therapy. ...The amount of iron excreted was 10%-15% of that obtained using the same dosage of deferoxamine …
We examined the effect of intranasal administration of deferoxamine on iron excretion in seven patients with iron overload sec …
24 results
Jump to page
Feedback